Table 4. Determinants of the assignment of treatment modification.

	Odds ratio (95% confidence interval)	p value
Family history of premature CHD, n = 419	2.67 (1.71-4.18)	< 0.01
Secondary prevention, n = 417	2.07 (1.32-3.24)	< 0.01
Metabolic syndrome element*
Abnormal triglycerides, n = 417	1.65 (1.10-2.48)	0.02
Impaired fasting glucose, n = 417	2.58 (1.56-4.28)	< 0.01
Patients have been given a target cholesterol level, n = 294	2.89 (1.67-5.02)	< 0.01
Patients were aware of not achieving targets, n = 412	1.82 (1.13-2.94)	0.01
Patients seen for cholesterol checkup less frequently than every 3 months, n = 402	2.40 (1.41-4.08)	< 0.01
Frequency of lipid-lowering medications missed more than once a week, n = 227	2.85 (1.44-5.65)	< 0.01
Satisfied with the level of information available to them about high cholesterol, n = 315	2.30 (1.21-4.39)	0.01
Feelings toward cholesterol management
Confused, n = 334	0.25 (0.10-0.62)	< 0.01
No strong feeling, n = 347	3.80 (2.28-6.32)	< 0.01

* Abnormal triglyceride (≥ 150 mg/dL); impaired fasting glucose (≥ 100 mg/dL).

CHD, coronary heart disease